anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Provided is novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies and pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies are also provided. The compounds and pharmaceutical compositions can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases. CONSTITUTION: Provided are novel compounds, formulations and methods which may be used in the study, diagnosis, treatment or prevention of diseases and conditions which relate to cell adhesion, including, but not limited to arthritis, asthma, allergies, adult respiratory distress syndrome, cardiovascular disease, thrombosis or harmful platelet aggregation, allograft rejection, neoplastic disease, psoriasis, multiple sclerosis, CNS inflammation, Crohn's disease, ulcerative colitis, glomerular nephritis and related inflammatory renal disease, diabetes, ocular inflammation (such as uveitis), atherosclerosis, inflammatory and autoimmune diseases. Pharmaceutical formulations containing these VLA-4-mediated cell adhesion inhibitors and methods of using the compounds and compositions of the invention for inhibition of cell adhesion. According to one embodiment, these novel compounds, compositions and methods are advantageously used to treat inflammatory and immune diseases. Methods for preparing the compounds and intermediates useful in those methods are also provided. Accordingly, provided is cell adhesion inhibitors comprising a compound having Formula(I)A-B.
The present invention relates to a method for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (CRFR). Further, the present inventi on relates to an antagonist of the ligand of the corticotropin-releasing factor  receptor (CRFR) comprising or alternatively consisting of the amino acid sequence of astressin wherein at least Ala at position 11 is replaced by another amino acid. Further, the present invention relates to an antibody directed against the agonist or antagonist of the present invention. Also described is an anti-idiotypic antibody which is directed against the antibody(ies) of the invention. The present invention also relates to a pharmaceutical or diagnostic composition comprising the antagonist, the agonist, the antibody(ies) and/or the anti-idiotypic antibody of the invention. Furthermore, the present invention relates to a kit comprising th e agonist, the antagonist, the antibody(ies) and/or the anti-idiotypic antibod y of the present invention. Also described is the use of the agonist, the antagonists, the antibody(ies) and/or the anti-idiotypic antibody of the invention for the preparation of a pharmaceutical composition for the treatment, diagnosis and/or prevention of corticotropin-releasing factorrece ptor-associated diseases. The present invention also relates to a method of refining the agonist and/or the antagonists of the present invention by means of peptidomimetics and synthesizing the refined compound. Furthermore,  the present invention relates to a method of formulating the agonist/antagonist of the invention into a pharmaceutical composition.</SDOA B>
This study sought to enroll opioid dependent women under supervision in the criminal justice system and in a controlled environment (substance abuse treatment)but at at high risk for opioid relapse and engaging in HIV risk behaviors when returning to the community. Initially, 9 women were enrolled and received buprenorphine medication. After the first 9 participants, women were randomized to either buprenorphine or placebo. Women received the buprenorphine medication for 12 weeks in the community and at the end of the 12 weeks were transitioned either to another buprenorphine provider, methadone provider, or tapered off buprenorphine based on the participant's preferences. One additional follow-up at 3 months after treatment was conducted. The primary outcome was opioid positive urines at all time points.
The invention provides a recombinant virus vector for use as an immunotherapeutic or vaccine. The recombinant virus vector comprises at least one pair of nucleotide sequences heterologous to the virus and which have sufficient sequence homology that recombination between them might be expected. The pair of nucleotide sequences are arranged in the virus vector such that they are inverted with respect to each other. The virus vector is able to infect a mammalian host cell and express as polypeptide the heterologous nucleotide sequences in the host cell. For infection thought to be caused by HPV infection, the pair of nucleotide sequences encode part or all of human papillomavirus (HPV) wild-type proteins or mutant proteins immunologically cross-reactive therewith. For an immunotherapeutic or vaccine against cervical cancer, the recombinant virus vector encodes part or all of the HPV wild-type proteins HPV16E7 and HPV18E7 or mutant proteins immunologically cross-reactive therewith.
Disclosed embodiments provide a computer-implemented technique for selection and/or modification of surgical simulation scenarios based on patient similarity cohort identification. Prior to undergoing surgery, medical information of a patient, including genomic, physiological, and/or environmental data, is used to identify a patient cohort. The patient cohort represents a statistically significant sample size of similar patients, and complications that may have arose during similar surgical procedures to the procedure planned for the patient. Relevant scenarios are identified based on the patient cohort. These scenarios are then input to a surgical simulation system. The surgical simulation system may be implemented by virtual reality, augmented reality, and/or physical workpieces used for surgical practice and training. This can increase the probability of a successful outcome for the patient, and furthermore save costs by reducing the risk of malpractice lawsuits, thereby potentially lowering overall healthcare costs.
PROBLEM TO BE SOLVED: To obtain the subject stable cosmetic having excellent antibacterial activity and giving low stimulation to the skin by combining a polyhydric alcohol (alkyl ether) with extract or crushed product of the internal seed coat of ginkgo. SOLUTION: The objective cosmetic is produced by compounding (A) 5.0-10.0 pts.wt. of (i) a polyhydric alcohol preferably having <=4 hydroxyl groups in the molecule and/or (ii) a polyhydric alcohol alkyl ether, preferably an alkyl ether of glycols or glycerol with (B) an extract or crushed product of the internal seed coat of ginkgo produced by crushing dried or heat-treated internal seed coat of ginkgo, extracting with 2-1,000 pts.wt. (based on 1 pt.wt. of the seed coat) of a polar solvent (e.g. ethanol) at room temperature under normal pressure at a temperature below the boiling point of the solvent for 2 hr to 2 weeks and optionally subjecting the extract to deodorization, purification, drying, etc., and, as necessary, (C) various conventional components for cosmetics.
ED staff refer suicidal patients not admitted to an inpatient unit to the off-site Suicide Prevention Consultation Center (SPCC). SPCC clinicians will deliver SPI+ (Safety Planning Intervention plus 2 or more post-discharge telephone calls) to patients via telehealth.
Age-Related Macular Degeneration (AMD) is a sight-threatening visual disturbance that affects the macula in older ages. It is irreversible if the pigment epithelium is lost (dry AMD), but wet AMD can be arrested or delayed with the use of intraocular injections of one of 3 different compounds. All three drugs are injected into the eye in minute doses of usually 0.1 ml. These are usually injected at 4 to 6 week intervals and treatment may be extended for several years. Different patterns of injection times are followed but usually are monthly for 12 or more months, or monthly for 3 months and then extended observation at one to two month intervals unless vision (visual acuity) declines or Optical Coherence Tomography-angiography (OCT-A) shows recurrence of fluid or increase in size or amount of drusen (deposits of lipofuscin) in the retina. Vitelliform macular degeneration is a disorder that causes visual loss due to drusen in the macula, which have been shown to be identical to the deposits seen in macular degeneration. The goal of therapy in this proposal is to use sildenafil to increase choroidal blood flow to treat dry AMD and slow the progression of visual loss in vitelliform and age-related dry AMD as well as other macular, retinal and choroidal degenerations and dystrophies, as well as reduce or eliminate the number of injections required by slowing down transformation of dry AMD to wet AMD in treated patients.
PROBLEM TO BE SOLVED: To obtain a myocardial protective fluid capable of protecting hypertrophic myocardium getting easily ischemic or morbid myocardium, enabling safe operation in bloodless visual field without the need of using any local hypothermia, and enabling favorable cardiac function recovery, by combining histidine with a specific compound in specified proportions. SOLUTION: This myocardial protective fluid contains a combination of 90-110 (esp. 100) mM/L of histidine with 0.05-2 (esp. 0.1) mM/L of adenosine. Owing to the combination, the necessary amount of the histidine to be used becomes minimum and production of histamine can be suppressed to a minimum. Besides, it is preferable that the fluid contains glucose serving as the substrate of glycolytic system (9-12mM/L), insulin to raise glucose intake into cells (7.1-121U/L) and lidocaine as a Na channel blocker (60-120mg/L). This fluid is optimum for preserving hypertrophic myocardium, and pref. has its pH at 7.7-7.9.
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor and is described chemically as: 

6-(cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide.

The molecular formula is C20H19D3N8O3 and the molecular weight of the free base is 425.47. Deucravacitinib has the structural formula:

Deucravacitinib is a white to yellow powder. The solubility of deucravacitinib is pH dependent. Solubility decreases with increasing pH.

SOTYKTU (deucravacitinib) tablets are supplied in 6 mg strength for oral administration. Each tablet contains deucravacitinib as the active ingredient and the following inactive ingredients: anhydrous lactose, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicon dioxide. In addition, the film coating Opadry® II Pink contains the following inactive ingredients: iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Background: Traumatically injured patients continue to be plagued with uncontrolled hemorrhage resulting in significant morbidity and early mortality. A primary driving force for this unbridled hemorrhage is known to be the early coagulopathy which complicates severe injury. Trauma induced coagulopathy has been postulated to be an equilibrium imbalance between pro and anticoagulant factors, platelets, endothelium and fibrinolysis soon after injury. Recent evidence demonstrates that the early use of the antifibrinolytic agent tranexamic acid (TXA) after trauma center arrival results in improved survival in patients at risk for bleeding. Bringing this proven treatment to the prehospital arena and intervening earlier in those patients who would otherwise not be candidates for treatment has the real potential to further reduce or prevent the vicious hemorrhagic cascade, improve clinical outcomes and provide insight into the underlying mechanisms responsible for and which maximize its benefit.

Objective/Hypothesis: The primary hypothesis will be that prehospital infusion of tranexamic acid in patients at risk for bleeding will reduce the incidence of 30 day mortality. The secondary hypotheses include that prehospital tranexamic acid will reduce the incidence of hyperfibrinolysis, acute lung injury, multiple organ failure, nosocomial infection, mortality, early seizures, pulmonary embolism and early resuscitation needs, reduce or prevent the early coagulopathy as demonstrated by improving presenting INR and rapid thromboelastography parameters, reduce the early inflammatory response, plasmin levels, leukocyte, platelet and complement activation, and determine the optimal dosing of tranexamic acid post-injury.
PURPOSE: Retinal degeneration (RD) is a large cluster of retinopathies that is characterized by the progressive photoreceptor death and visual impairments. CX3CL1/CX3CR1 signaling has been documented to mediate the microglia activation and gliosis reaction during neurodegeneration. We intend to verify whether the CX3CL1/CX3CR1 signaling is involved in the RD pathology.
METHODS: A pharmacologically induced RD mice model was established. AZD8797, a CX3CR1 antagonist, was injected into the vitreous cavity of an RD model to modulate the neuroglia activation. Then, the experimental animals were subjected to functional, morphological, and behavioral analysis.
RESULTS: The CX3CL1/CX3CR1 signaling mediated neuroglia activation was implicated in the photoreceptor demise of an RD model. Intravitreal injection of AZD8797 preserved the retinal structure and enhanced the photoreceptor survival through inhibiting the CX3CL1/CX3CR1 expressions. Fundus photography showed that the distribution of retinal vessel was clear, and the severity of lesions was alleviated by AZD8797. In particular, these morphological benefits could be translated into remarkable functional improvements, as evidenced by the behavioral test and electroretinogram (mf-ERG) examination. A mechanism study showed that AZD8797 mitigated the microglia activation and migration in the degenerative retinas. The Müller cell hyper-reaction and secondary gliosis response were also suppressed by AZD8797.
CONCLUSIONS: The neuroinflammation is implicated in the photoreceptor loss of RD pathology. Targeting the CX3CL1/CX3CR1 signaling may serve as an effective therapeutic strategy. Future refinements of these findings may cast light into the discovery of new medications for RD.
The invention relates to a natural dandruff-removing and itching-relieving liquid shampoo which is prepared, by weight, by olive oil, polygonum multiflorum, Chinese honeylocust fruit and orange peel. The natural dandruff-removing and itching-relieving liquid shampoo does not contain any chemical substances, is non-toxic and harmless, and cannot cause any damage to human health. The natural dandruff-removing and itching-relieving liquid shampoo enables hair to be smooth, enables dry hair to be manageable and to have silk quality in the sense of touch, and also enables the hair to be brilliantly black, soft, bright, but not oily, full of vigor and elasticity, and healthy. The natural dandruff-removing and itching-relieving liquid shampoo is mild and natural in smell and not tangy, and a delicate fragrance lasts after the natural dandruff-removing and itching-relieving liquid shampoo is used. The natural dandruff-removing and itching-relieving liquid shampoo produces fine, smooth and rich foam, pasty fluid is continuous, stickiness is high, the natural dandruff-removing and itching-relieving liquid shampoo is easy to wash out, and the hair is not sticky. After the natural dandruff-removing and itching-relieving liquid shampoo is used, the hair is light, natural and smooth, and the phenomenon that hair cannot be combed through does not exist.
Provided are an immune composition, a preparation method therefor, and a use thereof. In the present invention, a prokaryotic expression system or a recombinant adenovirus system is used to highly efficiently express VZV envelope gE glycoprotein and the flagellin fusion protein thereof. The produced recombinant gE protein, gE flagellin fusion protein, and recombinant adenovirus vector, or compositions thereof is used to immunize a mouse so as to promote the body to generate high levels of gE and VZV specific antibody titer, as well as gE and VZV specific cell immunity. The present invention has relatively good immunogenicity and can be developed into a new generation of modified VZV vaccines. Unlike the commercial attenuated vaccines currently available, the vaccines developed using the present invention would not make vaccine receiver suffer the risk of contracting Shingles. In addition, the vaccines developed using the present invention have lower side effect than existing subunit Shingles vaccines containing adjuvant gE.
Capecitabine 1000 mg/m\^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
High-efficiency plasma skimming is hopeful to prevent hemolysis inside spiral groove bearings (SGBs) because it can exclude red blood cells from the ridge gap with a high shear force. However, no study reveals the shape design of SGBs to improve plasma skimming. Therefore, this study proposed and applied a groove design strategy to designing an optimal SGB for enhancing plasma skimming in a rotary blood pump (RBP). Initially, we proposed the design strategy that the shape of the groove for enhancing plasma skimming corresponds to the direction of blood flow in the ridge gap. Second, we visualized the cell flow in a specially designed experimental RBP to determine the direction of blood flow, which was helpful in the subsequent SGB design. Then, we created an SGB to provide superior plasma skimming and applied it to the experimental RBP. We evaluated the plasma skimming effect of SGB at rotational speeds ranging from 2400 to 3000 rpm and hematocrit conditions between 1% and 40%. At a 1% hematocrit, the plasma skimming efficiency for the entire SGB was greater than 95%. In all hematocrit conditions, the efficiency at the inner ridges of the SGB was greater than 80%. The results showed the designed SGB successfully induced excellent plasma skimming within ridge gaps. This study is the first to propose and apply a shape design strategy to generate excellent plasma skimming within an SGB. This study may contribute to the prevention of SGB hemolysis inside SGB for use in RBPs.
Sepsis is a severe inflammatory disease characterized by cytokine storm, often accompanied by disseminated intravascular coagulation (DIC). PANoptosis is a novel form of cell death triggered by cytokine storms, characterized by a cascade reaction of pyroptosis, apoptosis, and necroptosis. It exists in septic platelets and is closely associated with the onset and progression of DIC. However, there remains an unmet need for drugs targeting PANoptosis. The anti-PANoptosis effect of myricetin was predicted using network pharmacology and confirmed through molecular docking. In vitro platelet activation models demonstrated that myricetin significantly attenuated platelet particle release, integrin activation, adhesion, spreading, clot retraction, and aggregation. Moreover, in a sepsis model, myricetin reduced inflammatory infiltration in lung tissue and platelet activation while improving DIC. Additionally, whole blood sequencing samples from sepsis patients and healthy individuals were analyzed to elucidate the up-regulation of the PANoptosis targets. Our findings demonstrate the inhibitory effect of myricetin on septic platelet PANoptosis, indicating its potential as a novel anti-cellular PANoptosis candidate and therapeutic agent for septic DIC. Furthermore, our study establishes a foundation for utilizing network pharmacology in the discovery of new drugs to treat various diseases.
Although infectious processes of the lungs are common in these immunosuppressed patient collectives, non-infectious causes account for up to half of the pulmonary manifestations found in hematologic malignancies. Besides the frequent infections including opportunistic pathogens, a broad differential diagnosis including drug-induced lung injury by cytostatic substances, cytokines, and innovative immunotherapeutic agents, rarer transfusion of blood products, and intrathoracic manifestations of the hematologic malignancy itself, must be kept in mind. Finally, vascular complications can also lead to pulmonary reactions. Early and consistent diagnostics and treatment of bronchopulmonary, intrathoracic, and vascular complications within the framework of hematologic systemic diseases can be essential for the patient's prognosis. Up to 25% of patients with profound neutropenia lasting for \>10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in most cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation.

In patients who do not improve rapidly with first-line therapy with broad spectrum antibiotics, cross-sectional thoracic CT imaging is essential. It provides much better definition of the pattern of radiological changes that includes three main groups: consolidation, nodules (micro- and macro-), and diffuse changes, as ground glass pattern. Discuss these radiological patterns and how this guides the appropriate initial investigations and treatment options will be of a great value to be followed.
Pancreas transplantation is a complex surgical procedure performed to restore normoglycemia in patients with type 1 diabetes and includes whole/segmental organ transplant and islet cell transplantation (ICT). In the United States, simultaneous pancreas-kidney transplant (SPK) is most commonly performed due to the higher occurrence of end-stage renal disease in diabetic patients. Understanding the surgical technique and postoperative anatomy is imperative for effective and accurate surveillance following transplantation. Imaging plays an essential role in patients with pancreatic transplants and is often used to evaluate viability, vascular and parenchymal anatomy, and identify potential complications. Imaging techniques such as ultrasound, color and spectral Doppler, computed tomography (CT), magnetic resonance imaging (MRI), and angiography have a complementary role in the postoperative evaluation following a pancreas transplant. The common complications after a whole organ pancreas transplant include vascular thrombosis, graft rejection, pancreatitis, and infections. Complications can be classified into vascular (partial or complete venous thrombosis, arterial thrombosis, stenosis or pseudoaneurysm), parenchymal (pancreatitis, graft rejection), and bowel-related or miscellaneous causes (bowel obstruction, anastomotic leak, and peripancreatic fluid collections). Islet cell transplantation is an innovative therapy for patients with type 1 diabetes. It involves isolating insulin-producing islet cells from donor pancreas and transplanting into recipients, to provide long-term insulin independence or significantly reduce insulin requirements. In recent years, isolation techniques, immunosuppressive regimens, and post-transplant monitoring advancements have propelled ICT as a viable therapeutic option. This comprehensive review aims to provide insights into the current state-of-the-art imaging techniques discussing both normal and abnormal features following pancreas transplantation.
FIELD: medicine. SUBSTANCE: the product of the formula 1 presented in the specification wherein Y is CH; n is 0-3; m is 0-1 provided that m is 1 when n is 0, and m is 0 when n is 1-3. Reagent 1: a corresponding ester. Reagent 2: an acid. Reaction conditions: acid hydrolysis is carried out at 50-150 C. The compound is used as an antagonist of stimulating aminoacid receptors. EFFECT: Improved properties of the tetrazole derivatives. 1 tbl